SCHEMBL25866513

SCHEMBL25866513

CCCNc1ccc(N)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
ALOX15 P16050 2/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP3A4 P08684 3/20 0.45
TSHR P16473 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
MAPT P10636 3/20 0.40
CISD1 Q9NZ45 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
IDO1 P14902 1/20 0.40
HSD17B10 Q99714 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11315849 0.89 TLR8 (0.46) ALDH1A1ALOX15GAAHTTTDP1
SCHEMBL3786327 0.84 ALDH1A1 (0.48) ALDH1A1ALOX15GAAHTTTDP1
SCHEMBL22860566 0.83 ALDH1A1 (0.44) ALDH1A1ALOX15GAAHTTTDP1
SCHEMBL7531364 0.82 LMNA (0.58) ALDH1A1GAAHTTTDP1TSHR
SCHEMBL3863277 0.81 HTR2C (0.48) ALDH1A1ALOX15GAAHTTTDP1
SCHEMBL18893491 0.81 LMNA (0.45) ALDH1A1GAAHTTSMN1; SMN2LMNA
SCHEMBL15196187 0.81 ALDH1A1 (0.45) ALDH1A1ALOX15GAAHTTCYP3A4
SCHEMBL5162037 0.81 ALDH1A1 (0.46) ALDH1A1ALOX15GAAHTTTDP1
SCHEMBL19026909 0.80 ALDH1A1 (0.42) ALDH1A1ALOX15GAAHTTTDP1
SCHEMBL9499759 0.80 PTGER4 (0.50) ALDH1A1ALOX15GAAHTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691972-B2 Compounds for targeted degradation of BRD9 C4 THERAPEUTICS, INC. (US) 2023-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691972-B2 Compounds for targeted degradation of BRD9 BRD9, BRD1, BRWD1 ALDH1A1 4230/4885ALOX15 4556/4885GAA 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.